GBA Presents: RADIO SAVANT-!

stonedinvestor said:
Hello Hello. TED!!!!

I am on the move. I have cut things very close. My wife is very mad at me. I am afraid of Dr's/

My mouth is a mess I am living in fear... Mt Dentist is retiring this is her last appointment it's Tues...I have to go.

Monday I have this horrible Christmas party I have to go to. I'm not going to be in good shape.

... It's questionable how this all works out-- will she have enough time to fix me? Will she try and say I need a root canal. Shhhhhhhhh SHUT UP! What then? what do I do with this hole in my mouth three days before Christmas...or is it two holes in the mouth? Mt wife wans to be in Ct.
... anyway I'm eating mushroom chocolate bars now.

More...
Stoney!!!!
There you are.

What a win by our big blue machine!
See! Van gives the thumbs-up and these dogs have a chance at the playoffs.
:thumbsup:
 

It's D-Day :mad:

-Tapestry initiated with an Outperform at Raymond James 07:26 TPR Raymond James analyst Rick Patel initiated coverage of Tapestry with an Outperform rating and $44 price target. Expectations are low and already reflect macro headwinds affecting most global brands, Patel tells investors in a research note. The firm's estimates embed a low single digit percentage revenue decline in FY23 and below-algorithm growth in FY24.
 

Rivian Automotive initiated with an Overweight at Cantor Fitzgerald 07:18 RIVN Cantor Fitzgerald analyst Andres Sheppard initiated coverage of Rivian Automotive (RIVN) with an Overweight rating and $22 price target. Rivian benefits from a differentiated product offering, a strong backing from Amazon (AMZN), and a proprietary charging network, but shares are down ~79% YTD, so this could be a good entry point, Sheppard tells investors in a research note.

DexCom price target raised to $130 from $120 at Stifel 07:12 DXCM

Next Hydrogen Solutions to receive investment of $5.1M from SDTC 07:09 NXHSF Next Hydrogen Solutions announces that it has been awarded $5.1M from Sustainable Development Technology Canada, SDTC, towards the development and demonstration of the Company's next generation electrolysis technology. This collaborative project with a budget of over $12M will run to the end of 2024, resulting in cost and performance improvements to Next Hydrogen's current line of electrolysis products and the launch of next generation large-scale electrolysis modules. With the launch of these products, Next Hydrogen will be well positioned to support the needs of its customers for both near-term market demonstrations and commercial large-scale green hydrogen systems. "We are delighted with SDTC's decision to support this Next Hydrogen led consortium project," says Raveel Afzaal, President and CEO of Next Hydrogen. "The collaboration with key industry partners provides an unprecedented opportunity to accelerate the adoption of our innovative green hydrogen products in the marketplace. We look forward to providing updates on our development progress and related market deployment projects."

Avient price target raised to $44 from $35 at Baird 06:53 AVNT Baird analyst Ben Kallo raised the firm's price target on Avient to $44 from $35 and keeps an Outperform rating on the shares. The analyst said COVID lockdown uncertainty and demand issues persist going into 2023, however, he is encouraged by the company's transition to a pure-play specialty formulator following the divestiture of its Distribution business.

Zymeworks upgraded to Buy at Jefferies with increased clarity » 06:46 ZYME

UPGRADE OF THE DAY- BEAM

Beam Therapeutics upgraded to Outperform from Market Perform at BMO Capital 04:50 BEAM BMO Capital analyst Kostas Biliouris upgraded Beam Therapeutics to Outperform from Market Perform with a price target of $66, up from $61. The analyst expects "two key catalysts" from Beam's partner Verve to drive upside in the shares. In addition, incremental updates from Beam's pipeline programs and/or new partnership announcements can also drive the stock higher, Biliouris tells investors in a research note. In 2023, the analyst expects Verve to provide updates on management's response to the FDA on the VERVE-101 clinical hold and the first clinical data from VERVE-101 that "derisk base editing." Biliouris believes Beam's risk/reward is now skewed to upside.
 

Cathie Wood's ARKK hits a new 5-year low
Dec. 20,
image_1239809188.jpg


This Big I swear! They just make them different on the planet Kepler-62f
 
You must log in or register to reply here.
Back
Top